Revolutionising global vaccine access: The case for Stablepharma’s fridge-free vaccine technology

Revolutionising global vaccine access: The case for Stablepharma’s fridge-free vaccine technology Stablepharma is focused on improving global vaccine access with its leading candidate, SPVX02. Here, they discuss the challenges of vaccine development and distribution, and highlight how their platform could transform accessibility through fridge-free vaccines. In an era where vaccine equity remains one of the most critical challenges in global health, technological innovation offers a transformative opportunity. One such innovation, pioneered by Stablepharma, is set to redefine the future of vaccine distribution and access: a platform to reformulate existing vaccines into thermostable, fridge-free versions.